No connection

Search Results

ABUS vs TBPH

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
TBPH
Theravance Biopharma, Inc.
NEUTRAL
Price
$16.72
Market Cap
$861.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABUS
--
TBPH
8.12
Forward P/E
ABUS
-27.41
TBPH
12.34
P/B Ratio
ABUS
11.38
TBPH
2.88
P/S Ratio
ABUS
61.92
TBPH
8.01
EV/EBITDA
ABUS
-29.91
TBPH
-297.73

Profitability

Gross Margin
ABUS
-79.23%
TBPH
65.19%
Operating Margin
ABUS
-727.31%
TBPH
43.6%
Profit Margin
ABUS
-237.88%
TBPH
98.54%
ROE
ABUS
-38.52%
TBPH
44.84%
ROA
ABUS
-14.94%
TBPH
-0.54%

Growth

Revenue Growth
ABUS
-33.2%
TBPH
144.7%
Earnings Growth
ABUS
--
TBPH
--

Financial Health

Debt/Equity
ABUS
0.05
TBPH
0.14
Current Ratio
ABUS
15.73
TBPH
10.93
Quick Ratio
ABUS
15.52
TBPH
10.73

Dividends

Dividend Yield
ABUS
--
TBPH
--
Payout Ratio
ABUS
0.0%
TBPH
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
TBPH NEUTRAL

TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.

Strengths
Explosive YoY revenue growth of 144.70%
Exceptional liquidity with a Current Ratio of 10.93
Very low leverage with a Debt/Equity ratio of 0.14
Risks
Strongly bearish insider activity with 5 sell transactions and 0 buys
Bearish technical trend (0/100 score)
Highly volatile quarterly earnings track record with frequent misses

Compare Another Pair

ABUS vs TBPH: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile